

Raltegravir

Catalog No. HRP-11680

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

NIH HIV Reagent Program

Manufacturer:

Biosynth® Carbosynth, Newbury, England, United Kingdom or AK Scientific, Inc., Union City, California, USA

Product Description:

Raltegravir (brand name: Isentress®; also referred to as MK-0518 and raltegravir potassium) is an orally bioavailable human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. Inhibition of the viral integrase prevents the insertion of HIV DNA into the human DNA genome, blocking the ability of HIV-1 to replicate. Raltegravir inhibits the spread of HIV-1 IIIB infection in MT-4 cell culture with 95% cell culture inhibitory concentration values of 19 nM and 31 nM in medium containing 10% heat-inactivated fetal bovine serum or 50% normal human serum. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.¹

Material Provided:

Each vial contains approximately 2.0 mg of raltegravir (potassium salt).

Note: Raltegravir is soluble in water and dimethylsulfoxide (DMSO), but only slightly soluble in methanol and ethanol. It is insoluble in acetonitrile and isopropanol.

Packaging/Storage:

HRP-11680 was packaged in glass vials and is provided at room temperature. HRP-11680 should be stored at room temperature, in a cool, dry place. Once resuspended, working aliquots of HRP-11680 can be stored at -20°C. The vial should be centrifuged prior to opening.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Raltegravir, HRP-11680."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Trivedi, J., et al. "Recent Advances in the Development of Integrase Inhibitors for HIV Treatment." Curr. HIV/AIDS Rep. 17 (2020): 63-75. PubMed: 31965427.

ATCC® is a trademark of the American Type Culture Collection.

